Investor Relations

 

Common Stock

Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Overview

We aspire to become a world leader in AI-immunology, decoding the human immune system to develop effective immunotherapies for cancer and infectious diseases based on deep biological insights. We believe our ground-breaking AI-Immunology™ models PIONEER™, EDEN™ and RAVEN™, trained to simulate the immune system, can be harnessed to rapidly and cost-effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development. We have two personalized cancer immunotherapies in the clinic and are advancing a portfolio of vaccines to treat bacterial and viral infections. With an experienced management team, strong IP portfolio and scalable business model, Evaxion is well positioned for rapid growth.

Are you eager to deep-dive into Evaxion's business?
Download our company presentation below, or click here to see all our latest presentations.

Latest News

Press Release

Nov 28, 2023

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Press Release

Nov 15, 2023

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy

Press Release

November 6, 2023

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

Press Release

Oct 31, 2023

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

LATEST QUARTERLY EARNINGS (NASDAQ)

Subscribe to Investor Email Alerts

Be the first to know about news, milestones and events at Evaxion by subscribing to our investor email alerts.